文拉法辛治疗功能性胸痛的随机、双盲、安慰剂对照研究  

Effects of Venlafaxine in Treatment of Functional Chest Pain: A Randomized,Double-Blind,Placebo-Controlled Study

作　　者：石慧[1] 胡永东[1] 庞艳华[2] 王喆[3] 牛世芹[4] 张帆[3] 

机构地区：[1]首都医科大学附属北京朝阳医院临床心理科,北京100020 [2]首都医科大学附属北京朝阳医院消化内科,北京100020 [3]首都医科大学附属北京朝阳医院心内科,北京100020 [4]首都医科大学附属北京朝阳医院神经内科,北京100020

出　　处：《中国药学杂志》2012年第9期724-727,共4页Chinese Pharmaceutical Journal

摘　　要：目的评价文拉法辛治疗功能性胸痛的有效性及安全性。方法采用随机、双盲、安慰剂对照临床实验设计,共纳入符合功能性胸痛62名患者,分为药物组(文拉法辛75 mg.d-1)32名,对照组(安慰剂)30名。本试验为期6周的治疗,治疗前后进行症状量表、综合医院焦虑抑郁量表(HAD)和简明健康状况调查表(SF36)评估疗效及不良反应观察。结果采用意向治疗分析(ITT),6周后文拉法辛治疗有效率为71.4%,对照组治疗有效率为14.8%(χ2=17.912,P<0.001),两组疗效差异显著。文拉法辛组治疗后患者的焦虑抑郁评分较治疗前显著下降(P<0.05)。采用完成试验者分析(CA),两组SF36评分在生理职能、活力、情感职能3个维度方面比较差异有统计学意义(P<0.05)。药物组未见明显的不良反应。结论文拉法辛药物治疗功能性胸痛安全有效。OBJECTIVE To evaluate the clinical efficacy and safety of venlafaxine in treatment of functional chest pain （FCP）. METHODS In the randomized, double-blind, placebo-controlled clinical trial, 62 patients diagnosed with FCP was randomized to either trial group （venlafaxine, 75 mg· d^-1, 32 patients） or control group （placebo, 30 patients） for six weeks. The patients were in- terviewed to finish symptom assessment, hospital anxiety and depression scale （ HADS）, and 36-item short form health survey （ SF- 36）. RESULTS On the intention-to-treat analysis （ITT）, the effective rate of venlafaxine group was 71.4% and of placebo group was 14. 8%. The difference between the two groups was significant after six weeks （X^2 = 17. 912, P 〈0. 001 ）. The scores of anxiety and depression of venlafaxine group was significantly lowered after treatment （P 〈 0. 05 ）. On the completer analysis （ CA）, the differ- ence was statistically significant within three dimensions of SF-36 including the Physical Role, Vitality and Emotional Role （P 〈 0. 05 ）. Verdafaxine group had no significant side effect. CONCLUSION Venlafaxine is safe and effective in treatment of functional chest pain.

关 键 词：文拉法辛 功能性胸痛 内脏疼痛 

分 类 号：R969.4[医药卫生—药理学]